Director Jeffrey A. Meckler filed a Form 4 with the SEC on September 11, 2026, reporting the exercise of two stock options and the subsequent sale of 20,000 shares of Travere Therapeutics, Inc. common stock on September 10, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Option exercises: Meckler exercised two stock options on September 10, 2026, acquiring 10,000 shares at $17.44 and 10,000 shares at $26.52.
- Shares sold: A total of 20,000 shares were sold across four transactions at weighted average prices of $65.3917, $66.15, $67.4634, and $68.088 per share.
- Shares sold by lot: The four sale transactions covered 1,700 shares, 1,200 shares, 14,000 shares, and 3,100 shares, respectively.
- Remaining ownership: Following all reported transactions, Meckler directly beneficially owned 91,500 shares of common stock.
- Rule 10b5-1 plan: The filing states sales were made pursuant to a written plan adopted on June 11, 2026, meeting the requirements of Rule 10b5-1(c).
- Options fully vested: Both exercised stock options were reported as fully vested and exercisable at the time of exercise.
Jeffrey A. Meckler's Option Exercises and Share Sales at Travere Therapeutics
According to the filing, Jeffrey A. Meckler, a director of Travere Therapeutics, Inc. (NASDAQ:TVTX), exercised two stock options on September 10, 2026. The first option, originally granted on May 17, 2017 and expiring May 17, 2027, covered 10,000 shares at an exercise price of $17.44. The second, originally granted on May 9, 2018 and expiring May 9, 2028, covered 10,000 shares at an exercise price of $26.52. Both options were reported as fully vested. Following each exercise, the filing records show beneficial ownership rising to 101,500 shares and then 111,500 shares before the sales.
The filing reports four separate sale transactions, all on September 10, 2026, covering the 20,000 shares acquired through the option exercises. Specifically, 1,700 shares were sold at a weighted average price of $65.3917 (range: $64.835 to $65.81); 1,200 shares at a weighted average of $66.15 (range: $65.93 to $66.74); 14,000 shares at a weighted average of $67.4634 (range: $66.93 to $67.92); and 3,100 shares at a weighted average of $68.088 (range: $67.94 to $68.23). All sales are attributed to a written Rule 10b5-1(c) trading plan adopted on June 11, 2026. The filing notes that full information on the number of shares sold at each price within a range is available upon request from the SEC staff, the issuer, or any security holder.
After all reported transactions, Meckler's direct beneficial ownership in Travere Therapeutics common stock stood at 91,500 shares, according to the filing. The derivative securities table shows both stock options at zero remaining shares following the exercises.
What Was Disclosed
The Form 4 filed September 11, 2026 discloses that director Jeffrey A. Meckler exercised two stock options totaling 20,000 shares and sold those shares on September 10, 2026 under a pre-established Rule 10b5-1 plan, leaving him with 91,500 directly held shares.




Please wait processing your request...